(Q33514539)

27 July 2017

0 references

1 reference

title

A systematic review and meta-analysis of anti-adhesion molecule therapy in patients with active Crohn's disease (English)

1 reference

27 July 2017

0 references

1 reference

Yi Li

1

1 reference

27 July 2017

Yun Tian

2

1 reference

27 July 2017

Chao Yu

3

1 reference

27 July 2017

Weiming Zhu

4

1 reference

27 July 2017

Jieshou Li

5

1 reference

27 July 2017

publication date

1 January 2009

1 reference

Scandinavian Journal of Gastroenterology

27 July 2017

published in

1 reference

27 July 2017

volume

44

1 reference

27 July 2017

issue

12

1 reference

27 July 2017

page(s)

1435-1442

1 reference

Inflammatory bowel disease: clinical aspects and established and evolving therapies

27 July 2017

cites work

1 reference

https://api.crossref.org/works/10.3109%2F00365520903367254

The 10 remaining mysteries of inflammatory bowel disease

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00365520903367254

Inflammatory bowel disease: etiology and pathogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00365520903367254

Crucial role of the protein C pathway in governing microvascular inflammation in inflammatory bowel disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00365520903367254

Traffic signals for lymphocyte recirculation and leukocyte emigration: the multistep paradigm

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00365520903367254

alpha 4 integrins mediate lymphocyte attachment and rolling under physiologic flow

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00365520903367254

Lymphocyte homing and homeostasis

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00365520903367254

ICAM, an adhesion ligand of LFA-1, is homologous to the neural cell adhesion molecule NCAM.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00365520903367254

Crohn's disease: beyond antagonists of tumour necrosis factor

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00365520903367254

Review article: the expanding role of biological agents in the treatment of inflammatory bowel disease - focus on selective adhesion molecule inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00365520903367254

Anti-adhesion molecule therapies in inflammatory bowel disease: touch and go.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00365520903367254

Assessing the quality of reports of randomized clinical trials: is blinding necessary?

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00365520903367254

Does quality of reports of randomised trials affect estimates of intervention efficacy reported in meta-analyses?

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00365520903367254

Dose ranging pharmacokinetic trial of high-dose alicaforsen (intercellular adhesion molecule-1 antisense oligodeoxynucleotide) (ISIS 2302) in active Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00365520903367254

Absence of efficacy of subcutaneous antisense ICAM-1 treatment of chronic active Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00365520903367254

Double blind, placebo controlled trial of the remission inducing and steroid sparing properties of an ICAM-1 antisense oligodeoxynucleotide, alicaforsen (ISIS 2302), in active steroid dependent Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00365520903367254

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00365520903367254

Safety and tolerability of concurrent natalizumab treatment for patients with Crohn's disease not in remission while receiving infliximab.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00365520903367254

A placebo-controlled trial of ICAM-1 antisense oligonucleotide in the treatment of Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00365520903367254

A randomized placebo-controlled trial of a humanized monoclonal antibody to alpha4 integrin in active Crohn's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00365520903367254

Natalizumab for active Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00365520903367254

Natalizumab Induction and Maintenance Therapy for Crohn's Disease

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00365520903367254

Natalizumab for the treatment of active Crohn's disease: results of the ENCORE Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00365520903367254

Treatment of active Crohn's disease with MLN0002, a humanized antibody to the alpha4beta7 integrin

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00365520903367254

Apoptosis of T cells and the control of inflammatory bowel disease: therapeutic implications

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00365520903367254

Unravelling the pathogenesis of inflammatory bowel disease

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00365520903367254

Leukocyte adhesion: a suitable target for anti-inflammatory drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00365520903367254

Physiological basis for novel drug therapies used to treat the inflammatory bowel diseases. I. Immunology and therapeutic potential of antiadhesion molecule therapy in inflammatory bowel disease

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00365520903367254

Efficacy and safety of tumor necrosis factor antagonists in Crohn's disease: meta-analysis of placebo-controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00365520903367254

Adalimumab induction therapy for Crohn disease previously treated with infliximab: a randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00365520903367254

Tumor necrosis factor alpha antibody (infliximab) therapy profoundly down-regulates the inflammation in Crohn's ileocolitis.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00365520903367254

Anti-adhesion molecule strategies for Crohn disease

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00365520903367254

Progressive multifocal leukoencephalopathy after natalizumab therapy for Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00365520903367254

Progressive multifocal leukoencephalopathy in a patient treated with natalizumab

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00365520903367254

Evaluation of patients treated with natalizumab for progressive multifocal leukoencephalopathy

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00365520903367254

10.3109/00365520903367254

21 January 2018

Identifiers

DOI

1 reference

27 July 2017

1 reference